Fig. 4: D-Rd treatment reduces immunosuppressive CD38+ Tregs and MDSCs compared with Rd.
Panel a shows Treg population; panel b shows MDSC population. C cycle, D day, D-Rd daratumumab plus lenalidomide and dexamethasone, MDSC myeloid-derived suppressor cell, MSI mean signal intensity, Rd lenalidomide and dexamethasone, Treg regulatory T cell.
